|

Recombinant Humanized Bispecific antibody against HER2，KN026 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • Shanghai JMT-Bio Inc.1

Indications

  • First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer1
  • Breast Cancer1
  • Cancer1

Other1 trial

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.